IRCT20140810018747N1 IRCT 2021-06-27 Hamedan University of Medical Sciences Evaluation of the effect of probiotic prophylaxis in children with vesicoureteral reflux Evaluation of the effect of probiotic prophylaxis in children with vesicoureteral reflux referred to the pediatric nephrology ward of Hamadan’s Besat Hospital, Iran. 2021-06-22 anticipated 800 Complete https://irct.ir/trial/55829 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Permuted block randomization method was used. Random units were children with vesicoureteral reflux. “Blockrand()” function in R statistical package was used to generate a block randomization for this clinical trial. This function will randomize subjects to the specified treatments within sequential blocks. Permuted Block Randomization (PBR) consists of 200 blocks with block length 4. Permuted Block Randomization with block length 4 is denoted by PBR(4). In each block of PBR(4) half of the patients are assigned to the treatment groups A and B, respectively. The realization of the above program is as follows: [antibiotic prophylaxis group (B) and probiotic therapy group (A)], Blinding description: Control group with cephalexin capsule, which is odorless and cream-colored. The probiotic capsule treatment group is similar in structure, shape, color and odor to the control group and the drugs are indistinguishable in appearance. Due to the fact that patients are randomly assigned to groups, patients are not aware of the assigned treatment. In this study, participants enter the study based on designated blocks and without knowing the placement in groups. Patients are unaware of the placement in groups, but the facilitator (researcher) is aware of the placement and grouping. N/A Vesicoureteral-reflux. Intervention 1: Intervention group: Probiotic administration as prophylaxis, Yumogi probiotic {from Irianik company (Ardifarm Germany) containing Saccharomyces boulardii} with a dose of one 250 mg capsule at the bedtime . Intervention 2: Control group: no probiotics and prophylaxis antibiotics, prophylaxis with cephalexin (Farabi Pharmaceutical Company) 10 mg per kg body weight, once a day at the bedtime . Yes - There is a plan to make this available What will be shared: The results of this study are published in the title of the dissertation and the subsequent paper by Hamadan University of Medical Sciences. When: From 2023, access was provided. To whom: Researchers, physicians, nurses and medical students Conditions: Use the findings to improve patient care and develop research strategies. Where to obtain: Hamadan University of Medical Science How to obtain: Consult the Hamadan University of Medical Sciences' Central Library. Comments: